临床PI
嵇庆海 教授
教授,博士生导师
E-mail: jiqinghai@shca.org.cn
 

  1983年毕业于上海医科大学获临床医学学士学位,1993年获上海医科大学临床医学硕士学位,2002年晋升为主任医师。从事头颈部肿瘤外科33年,擅长于甲状腺癌、喉癌、下咽癌及舌癌的临床及基础研究。现任复旦大学附属肿瘤医院头颈部肿瘤多学科综合治疗组首席专家、中国抗癌协会甲状腺癌专业委员会副主任委员、中国医师协会甲状腺癌专业委员会副主任委员、上海抗癌协会甲状腺癌专业委员会主任委员、上海医学会普外科专业委员会甲状腺学组组长、中国抗癌协会头颈肿瘤专业委员会常委、上海抗癌协会头颈肿瘤专业委员会前任主任委员、意大利内分泌外科协会荣誉会员,担任《中华耳鼻咽喉---头颈外科杂志》、《中华外科杂志》、《中华肿瘤杂志》、《中国医学科学院学报》、《肿瘤》、《中国癌症杂志》、《Chinese Medical Journal》、《Medicine》、《World Journal of Surgical Oncology》及《Oncotargets and Therapy》杂志编委及审稿专家。主持国家科学基金面上项目五项、上海市科委重大项目、上海市基础研究重大项目及上海市重中之重项目多项,参与编写《肿瘤外科手术学》,沈镇宙主编,江苏科学技术出版社;《现代肿瘤学》,汤钊猷主编,复旦大学出版社;《外科学》七年制教材,陈孝平主编,人民卫生出版社;《口腔颌面头颈部肿瘤生物学》,陈万涛主编,上海交通大学出版社;发表论文50余篇,其中SCI收录30余篇,国内权威期刊10余篇。


研究领域:

  1.专业特长:头颈部肿瘤外科、甲状腺、唾液腺、口腔肿瘤、喉癌及喉咽癌的诊断和手术治疗。
  2.科研方向:头颈部肿瘤及甲状腺癌的基础及临床研究。

研究队伍:



代表性论著:

  1. Shi X, Liu XK, An CM, Wei WJ, Tao Y, Ji Y, Zhang Y, Han W, Xue JC, Huang NS, Ma B, Zhang CP, Yang X, Wang KJ, Liu QJ, Liu Y, Wang Y, Lei BW, Yu PC, Hu JQ, Lu ZW, Hu WP, Tian YX, Wang YL*, Ji QH*. Anatomic extent of lymph node metastases as an independent prognosticator in node-positive major salivary gland carcinoma: A study of the US SEER database and a Chinese multicenter cohort. Eur J Surg Oncol, 2019 Nov; 45(11):2143-2150.
  2. Lei BW#, Hu JQ#, Yu PC#, Wang YL, Wei WJ, Zhu J, Shi X, Qu N, Lu ZW*, Ji QH*. Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer. Eur Arch Otorhinolaryngol, 2019 Sep 11. doi: 10.1007/s00405-019-05597-0.
  3. Shi X#, Yu PC#, Lei BW#, Li CW, Zhang Y, Tan LC, Shi RL, Wang J, Ma B, Xu WB, Wang X, Hu JQ, Huang NS, Wei WJ, Wang Y, Chen TZ, Wang YL*, Ji QH*. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma. Thyroid, 2019 Sep; 29(9):1269-1278.
  4. Hu JQ#, Yu PC#, Shi X#, Liu WL, Zhang TT, Lei BW, Huang NS, Xu WB, Han LT, Ma B, Liao T, Wei WJ, Wang Y, Lu ZW, Wang YL*, Ji QH*. Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients with Major Salivary Gland Mucoepidermoid Carcinoma. J Cancer, 2019 Jul 22; 10(18):4380-4388.
  5. Han LT#, Hu JQ#, Ma B, Wen D, Zhang TT, Lu ZW, Wei WJ, Wang YL, Wang Y, Liao T*, Ji QH*. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis. Diagn Pathol, 2019 Jun 4; 14(1):52. doi: 10.1186/s13000-019-0832-2.
  6. Ma B#, Jiang H#, Wen D, Hu J, Han L, Liu W, Xu W, Shi X, Wei W, Liao T, Wang Y, Lu Z, Wang Y*, Ji QH*. Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer. J Clin Endocrinol Metab, 2019 Apr 3. [Epub ahead of print]
  7. Huang NS, Wei WJ, Qu N, Wang YL, Wang Y, Ji QH*. Lingual ectopic papillary thyroid carcinoma: Two case reports and review of the literature. Oral Oncol, 2019 Jan; 88:186-189.
  8. Ma B#, Wei W#, Xu W#, Wang Y, Guan H, Fan J, Zhao Z, Wen D, Yang S, Wang Y*, Chang B*, Ji QH*. Surgical Confirmation of Incomplete Treatment for Primary Papillary Thyroid Carcinoma by Percutaneous Thermal Ablation: A Retrospective Case Review and Literature Review. Thyroid,2018 Sep; 28(9):1134-1142.
  9. Shi X#, Huang NS#, Lei BW#, Song KH, Shi RL, Wei WJ, Hu WP, Dong F, Wang Y, Wang YL*, Ji QH*. Central Lymph Node Status has Significant Prognostic Value in the Clinically Node-Negative Tall-Cell Variant of Papillary Thyroid Cancer Regardless of T-Staging and Radioactive Iodine Administration: First Evidence From a Population-Based Study. Ann Surg Oncol, 2018 Aug; 25(8):2316-2322.
  10. Shi X#, Huang NS#, Shi RL#, Wei WJ, Wang YL*, Ji QH*. Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: first evidence from a SEER-based study. Cancer Manag Res, 2018 Jul 20; 10:2163-2172.
  11. Wei WJ#, Lu ZW#, Wen D#, Liao T, Li DS, Wang Y, Zhu YX, Wang ZY, Wu Y, Wang YL, Ji QH*.The Positive Lymph Node Number and Postoperative N-Staging Used to Estimate Survival in Patients with Differentiated Thyroid Cancer: Results from the Surveillance, Epidemiology, and End Results Dataset (1988-2008). World J Surg, 2018 Jun; 42(6):1762-1771.
  12. Liao T#, Wang YJ#, Hu JQ#, Wang Y, Han LT, Ma B, Shi RL, Qu N, Wei WJ, Guan Q, Xiang J, Chen JY, Sun GH, Li DS, Mu XM*, Ji QH*. Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro. Oncol Rep, 2018 May; 39(5):2185-2192.
  13. Ma B#, Xu W#, Wei W#, Wen D, Lu Z, Yang S, Chen T, Wang YL*, Wang Y*, Ji QH*. Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC. Int J Endocrinol, 2018 May 21. 2018:2383715.
  14. Shi X#, Dong F#, Wei W#, Song K, Huang N, Lu Z, Lei B, Yu P, Liu W, Wang Y, Sun G, Wang Y, Ji Q*. Prognostic significance and optimal candidates of primary tumor resection in major salivary gland carcinoma patients with distant metastases at initial presentation: A population-based study.Oral Oncol, 2018 Mar; 78: 87-93.
  15. Liao T#, Wei WJ#, Wen D#, Hu JQ, Wang Y, Ma B, Cao YM, Xiang J, Guan Q, Chen JY, Sun GH, Zhu YX, Li DS, Ji QH*. Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. J Cancer, 2018 Mar 29; 9(8):1329-1336.
  16. Wen D#, Liao T#, Ma B, Qu N, Shi RL, Lu ZW, Wang YL, Wei WJ*, Ji QH*. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.Cancer Med, 2018 Feb; 7(2):285-296. 
  17. Qu N#, Hu JQ#, Liu L, Zhang TT, Sun GH, Shi RL, Ji QH*. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl‑1 pathway.Int J Oncol, 2017 May; 50(5):1683-1692.
  18. Shi RL#, Qu N#, Luo TX#, Xiang J, Liao T, Sun GH, Wang Y, Wang YL, Huang CP, Ji QH*. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.Thyroid, 2017 Apr; 27(4):537-545. 
  19. Zhang TT#, Qu N#, Hu JQ, Shi RL, Wen D, Sun GH, Ji QH*. Mediastinal Lymph Node Metastases in Thyroid Cancer: Characteristics, Predictive Factors, and Prognosis. Int J Endocrinol, 2017; 2017:1868165.
  20. Sun GH#, Wang YJ#, Gao LL, Qu N, Mu XM, Shi RL, Ji QH*. Primary chondrosarcoma of the thyroid cartilage: Surgery-based management of a rare case. Oncol Lett, 2016 Dec; 12(6):4435-4438.
  21. Shi RL#, Qu N#, Yang SW#, Ma B, Lu ZW, Wen D, Sun GH, Wang Y, Ji QH*. Tumor size interpretation for predicting cervical lymph node metastasis using a differentiated thyroid cancer risk model.Onco Targets Ther, 2016 Aug 12; 9:5015-22.
  22. Shi RL#, Qu N#, Lu ZW#, Liao T, Gao Y, Ji QH*. The impact of marital status at diagnosis on cancer survival in patients with differentiated thyroid cancer. Cancer Med, 2016 Aug; 5(8):2145-54.
  23. Shi RL#, Qu N#, Liao T, Wei WJ, Wang YL, Ji QH*. The Trend of Age-Group Effect on Prognosis in Differentiated Thyroid Cancer. Sci Rep, 2016 Jun 8; 6:27086.
  24. Shi RL#, Qu N#, Liao T, Wei WJ, Lu ZW, Ma B, Wang YL, Ji QH*. Relationship of body mass index with BRAF (V600E) mutation in papillary thyroid cancer. Tumour Biol, 2016 Jun; 37(6):8383-90.
  25. Shi RL#, Qu N#, Liao T, Wang YL, Wang Y, Sun GH, Ji QH*. Expression, clinical significance and mechanism of Slit2 in papillary thyroid cancer. Int J Oncol, 2016 May; 48(5):2055-62.
  26. Ma B#, Wang Y*, Yang S, Ji QH. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: A systematic review and meta-analysis. Int J Surg, 2016 Apr; 28:153-61.
  27. Qu N#,Shi RL#, Ma B, Gao Y, Wang Y, Ji QH*. The Prediction of Sonographic features and BRAF Mutation for Central Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: Reply. World Journal of Surgery, 2016 Mar; 40(3):761-3.
  28. Shi RL#, Liao T#, Qu N#,Liang F, Chen JY, Ji QH*. The Usefulness of Preoperative Thyroid-Stimulating Hormone for PredictingDifferentiated Thyroid Microcarcinoma. Otolaryngology - Head and Neck Surgery, 2016 Feb; 154(2):256-62.
  29. Qu N#, Shi RL#, Luo TX#, Wang YL, Li DS, Wang Y, Huang CP, Ji QH*. Prognostic significance and optimal cutoff of age in medullary thyroid cancer. Oncotarget, 2016 Feb 21. doi: 10.18632/oncotarget.7556.
  30. Shi RL#, Qu N#, Liao T#, Wei WJ, Lu ZW, Ma B, Wang YL, Ji QH*. Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer.TumourBiol, 2016 Jan 5.
  31. Qu N#, Zhang L#, Lu ZW#, Ji QH*, Yang SW, Wei WJ, Zhang Y. Predictive factors for recurrence of differentiated thyroid cancer in patients under 21 years of age and a meta-analysis of the current literature. Tumor Biology, 2015 Dec 22.
  32. Qu N#,Zhang L#,Lin DZ#, Ji QH*, Zhu YX, Wang Y. The impact of coexistent Hashimoto's thyroiditis on lymph node metastasis and prognosis in papillary thyroid microcarcinoma. Tumor Biology, 2015 Dec 21.
  33. Gao Y#, Qu N#,Zhang L#,Chen JY, Ji QH*. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma. Tumor Biology, 2015 Dec 17.
  34. Qu N#,Zhang L#,Ji QH*, ChenJY, Zhu YX, Cao YM, Shen Q. Risk Factors for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Meta-Analysis. World Journal of Surgery, 2015 Oct; 39(10):2459-70.
  35. Wang YL, Sun JG, Wang J, Wei WJ, Zhu YX, Wang Y, Sun GH, Xu K, Li H, Zhang L, Ji QH*. Schwannoma of the cervical esophagus: Report of 2 cases and a review of the literature. Ear Nose Throat J, 2015 Sep; 94(9):E10-3.
  36. Wei WJ, Wang YL, Li DS, Wang Y, Wang XF, Zhu YX, Pan XD, Wang ZY, Wu Y, Jin L, Wang JC, Ji QH*. Association study of single nucleotide polymorphisms in mature microRNAs and the risk of thyroid tumor in a Chinese population. Endocrine,2015 Jun; 49(2):436-44.
  37. Wei WJ#, Lu ZW#, Wang Y, Zhu YX, Wang YL, Ji QH*. Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies.Cancer Genet, 2015 Mar; 208(3):68-75.
  38. Wei WJ#, Lu ZW#, Li DS, Wang Y, Zhu YX, Wang ZY, Wu Y, Wang YL, Ji QH*. Association of the miR-149 Rs2292832 polymorphism with papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese population. Int J MolSci, 2014 Nov 14; 15(11):20968-81.
  39. Qu N#, Zhang L#, Lu ZW#, Wei WJZhang YJi QH*. Risk of malignancy in focal thyroid lesions identified by (18)F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography: evidence from a large series of studies. Tumour Biol, 2014 Jun; 35(6):6139-47. 
  40. Qu N#, Zhang L#, Ji QH*,Zhu YX, Wang ZY, Shen Q, Wang Y, Li DS. Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer, 2014 Dec 4;14:914.
  41. Wang YL, Li DS, Wang Y, Wang ZY, Ji QH*. Lymph node ratio for postoperative staging of laryngeal squamous cell carcinoma with lymph node metastasis. PLoS One, 2014 Jan 27; 9(1):e87037.
  42. Wang YL#, Feng SH#, Guo SC#, Wei WJ, Li DS, Wang Y, Wang XF, Wang ZY, MaYY, JinL, Ji QH,Wang JC*. Confirmation of papillary thyroid cancer susceptibilityloci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35and 8p12 ina Chinese population. J Med Genet, 2013 Oct; 50(10):689-95.
  43. Sun G#, Wang Y, Zhu Y, Wang Y, Xu K, Wei W, Li H, Lu Z, Ji QH*. Lymph node metastasis between sternocleidomastoid and sternohyoid muscle in clinically node-positive papillary thyroid carcinoma. Head Neck, 2013 Aug; 35(8):1168-70.
  44. Wei WJ#, Wang YL#, Li DS#, Wang Y, Wang XF, Zhu YX, Yang YJ, Wang ZY, MaYY, Wu Y, JinL, Ji QH, Wang JC*. Association between thers2910164 Polymorphism in Pre-Mir-146aSequence and Thyroid Carcinogenesis. PLoS One, 2013; 8(2):e56638.
  45. Zhang L#, Li H#, Ji QH#, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y*. The clinical features of papillary thyroid cancer in Hashimoto’sthyroiditis patients from an area with a high prevalence of Hashimoto’s disease. BMC Cancer, 2012 Dec 21; 12:610.
  46. Wang YL#, Zhu YX#, Chen TZ#, Wang Y, Sun GH, Zhang L, Huang CP, Wang ZY, Shen Q, Li DS, Wu Y, Ji QH*. Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: experience of one cancer center 1997-2007. Acta Otolaryngol, 2012 Aug; 132(8):879-86.
  47. Zhang L#, Wei WJ#, Ji QH#Zhu YXWang ZYWang YHuang CPShen QLi DSWu Y.Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab, 2012 Apr; 97(4):1250-7.
  48. Wang Y#, Ji QH*, Li D, Wu Y, Zhu Y, Huang C, Shen Q, Wang Z, Zhang L, Sun T.Preoperative CT diagnosis of right nonrecurrent inferior laryngeal nerve. Head Neck,2011 Feb; 33(2):232-8.
  49. Zhang L, Zhu YX, Wang Y, Huang CP, Wu Y, Ji QH*.Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma: a 10-year experience. Ann SurgOncol, 2011 Jan; 18(1):233-8.
  50. Wang YL, Wang JC, Wu Y, Zhang L, Huang CP, Shen Q, Zhu YX, Li DS, Ji QH*. Incidentally simultaneous occurrence of RET/PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma. Cancer Lett, 2008 May 8; 263(1):44-52.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有